VP1 sequencing of all human rhinovirus serotypes: insights into genus phylogeny and susceptibility to antiviral capsid-binding compounds
- PMID: 15016887
- PMCID: PMC371056
- DOI: 10.1128/jvi.78.7.3663-3674.2004
VP1 sequencing of all human rhinovirus serotypes: insights into genus phylogeny and susceptibility to antiviral capsid-binding compounds
Abstract
Rhinoviruses are the most common infectious agents of humans. They are the principal etiologic agents of afebrile viral upper-respiratory-tract infections (the common cold). Human rhinoviruses (HRVs) comprise a genus within the family Picornaviridae. There are >100 serotypically distinct members of this genus. In order to better understand their phylogenetic relationship, the nucleotide sequence for the major surface protein of the virus capsid, VP1, was determined for all known HRV serotypes and one untyped isolate (HRV-Hanks). Phylogenetic analysis of deduced amino acid sequence data support previous studies subdividing the genus into two species containing all but one HRV serotype (HRV-87). Seventy-five HRV serotypes and HRV-Hanks belong to species HRV-A, and twenty-five HRV serotypes belong to species HRV-B. Located within VP1 is a hydrophobic pocket into which small-molecule antiviral compounds such as pleconaril bind and inhibit functions associated with the virus capsid. Analyses of the amino acids that constitute this pocket indicate that the sequence correlates strongly with virus susceptibility to pleconaril inhibition. Further, amino acid changes observed in reduced susceptibility variant viruses recovered from patients enrolled in clinical trials with pleconaril were distinct from those that confer natural phenotypic resistance to the drug. These observations suggest that it is possible to differentiate rhinoviruses naturally resistant to capsid function inhibitors from those that emerge from susceptible virus populations as a result of antiviral drug selection pressure based on sequence analysis of the drug-binding pocket.
Figures






Similar articles
-
Insights into the genetic basis for natural phenotypic resistance of human rhinoviruses to pleconaril.Antiviral Res. 2005 Dec;68(3):135-8. doi: 10.1016/j.antiviral.2005.08.003. Epub 2005 Sep 19. Antiviral Res. 2005. PMID: 16199099
-
Cryo-EM structure of pleconaril-resistant rhinovirus-B5 complexed to the antiviral OBR-5-340 reveals unexpected binding site.Proc Natl Acad Sci U S A. 2019 Sep 17;116(38):19109-19115. doi: 10.1073/pnas.1904732116. Epub 2019 Aug 28. Proc Natl Acad Sci U S A. 2019. PMID: 31462495 Free PMC article.
-
Human rhinovirus 3 at 3.0 A resolution.Structure. 1996 Oct 15;4(10):1205-20. doi: 10.1016/s0969-2126(96)00128-1. Structure. 1996. PMID: 8939746
-
Proposals for the classification of human rhinovirus species C into genotypically assigned types.J Gen Virol. 2010 Oct;91(Pt 10):2409-19. doi: 10.1099/vir.0.023994-0. Epub 2010 Jul 7. J Gen Virol. 2010. PMID: 20610666 Review.
-
Rhinovirus chemotherapy.Antiviral Res. 2006 Sep;71(2-3):391-6. doi: 10.1016/j.antiviral.2006.03.011. Epub 2006 Apr 18. Antiviral Res. 2006. PMID: 16675037 Free PMC article. Review.
Cited by
-
Targeting intercellular adhesion molecule-1 (ICAM-1) to reduce rhinovirus-induced acute exacerbations in chronic respiratory diseases.Inflammopharmacology. 2022 Jun;30(3):725-735. doi: 10.1007/s10787-022-00968-2. Epub 2022 Mar 22. Inflammopharmacology. 2022. PMID: 35316427 Free PMC article. Review.
-
Anno 2021: Which antivirals for the coming decade?Annu Rep Med Chem. 2021;57:49-107. doi: 10.1016/bs.armc.2021.09.004. Epub 2021 Nov 3. Annu Rep Med Chem. 2021. PMID: 34744210 Free PMC article.
-
New respiratory enterovirus and recombinant rhinoviruses among circulating picornaviruses.Emerg Infect Dis. 2009 May;15(5):719-26. doi: 10.3201/eid1505.081286. Emerg Infect Dis. 2009. PMID: 19402957 Free PMC article.
-
Modeling of the human rhinovirus C capsid suggests possible causes for antiviral drug resistance.Virology. 2014 Jan 5;448:82-90. doi: 10.1016/j.virol.2013.10.004. Epub 2013 Oct 20. Virology. 2014. PMID: 24314639 Free PMC article.
-
Identification of epidermal growth factor receptor-tyrosine kinase inhibitor targeting the VP1 pocket of human rhinovirus.Antimicrob Agents Chemother. 2024 Mar 6;68(3):e0106423. doi: 10.1128/aac.01064-23. Epub 2024 Feb 13. Antimicrob Agents Chemother. 2024. PMID: 38349161 Free PMC article.
References
-
- Arnold, E., and M. G. Rossmann. 1990. Analysis of the structure of a common cold virus, human rhinovirus 14, refined at a resolution of 3.0 Å. J. Mol. Biol. 211:763-801. - PubMed
-
- Bertino, J. S. 2002. Cost burden of viral respiratory infections: issues for formulary decision makers. Am. J. Med. 112:42S-49S. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources